Pacira Pharmaceuticals Getting Closer To Key Technical Measure

The Relative Strength (RS) Rating for Pacira Pharmaceuticals (PCRX) headed into a higher percentile Tuesday, as it got a lift from 67 to 71.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This exclusive rating from Investor’s Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock’s price movement over the last 52 weeks compares to all the other stocks in our database.

Decades of market research shows that the best-performing stocks often have an RS Rating of over 80 in the early stages of their moves. See if Pacira Pharmaceuticals can continue to rebound and clear that threshold.

See How IBD Helps You Make More Money In Stocks

Pacira Pharmaceuticals has moved more than 5% past a 68.18 entry in a second-stage cup without handle, meaning it’s now out of a proper buy range. The stock has held steady during the recent stock market pullback.

Look for the stock to offer a new buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week line. Read “Looking For The Next Big Stock Market Winners? Start With These 3 Steps” for more tips.


Earnings grew 42% last quarter, up from -71% in the prior report. Revenue also increased, from -26% to 12%.

Pacira Pharmaceuticals earns the No. 6 rank among its peers in the Medical-Biomed/Biotech industry group. Avid Bioservices (CDMO) and Vanda Pharmaceuticals (VNDA) are also among the group’s highest-rated stocks.


Biotech And Pharmaceutical Industry And Stock News

Which Stocks Are Showing Improved Price Performance?

Why Should You Use IBD’s Relative Strength Rating?

See How To Reduce Risk, Increase Profits With Swing Trading

Most Related Links :
Business News Governmental News Finance News

Source link

Back to top button